Categories
Daclizumab

Daclizumab

HY-108738
152923-56-3

MCE
CCR4 antagonist 2

CCR4 antagonist 2

HY-125836
2206788-99-8

MCE
HF51116

HF51116

HY-144347
2177311-29-2

MCE
MIF-IN-2

MIF-IN-2

HY-144194
2756410-57-6

$545.0 / 1mg

MCE
NRP1 antagonist 1

NRP1 antagonist 1

HY-133034
2569598-01-0

$121.0 / 10 mM * 1 mL in DMSO

MCE
MIF-IN-5

MIF-IN-5

HY-146318
2582755-31-3

MCE
Glofitamab

Glofitamab

HY-P99024
2229047-91-8

$580.0 / 1mg

MCE
Cibisatamab

Cibisatamab

HY-P99011
1855925-27-7

$680.0 / 1mg

MCE
Etokimab

Etokimab

HY-P99018
2022981-44-6

MCE
Isoandrographolide

Isoandrographolide

HY-N10359
4176-96-9

$300.0 / 1mg

MCE
Rafutrombopag (tautomerism)

Rafutrombopag (tautomerism)

HY-122620
2114365-78-3

$656.0 / 10 mM * 1 mL in DMSO

MCE
CXCR2 antagonist 4
Teplizumab

Teplizumab

HY-P99222
876387-05-2

MCE
Pinatuzumab

Pinatuzumab

HY-P99230
1639820-81-7

$300.0 / 1mg

MCE
Nemolizumab

Nemolizumab

HY-P99162
1476039-58-3

MCE
Anifrolumab

Anifrolumab

HY-P99168
1326232-46-5

MCE
Gevokizumab

Gevokizumab

HY-P99171
1129435-60-4

MCE
Uliledlimab

Uliledlimab

HY-P99169
2378407-27-1

$410.0 / 1mg

MCE
Relatlimab

Relatlimab

HY-P99156
1673516-98-7

MCE